Cortagen: why there is so little to say about it

Cortagen’s evidence is animal and cell work, and most of it comes from the St Petersburg group that designed the molecule. The one quantified result is a rat study: after their sciatic nerve was cut and re-stitched, rats given cortagen regrew nerve fibres 27% faster and carried signals 40% faster than controls [1]. A PubMed search in September 2026 returned 15 records mentioning it, almost all in rats, mice or cells [7]. No human trial of it exists, published or registered, and the single abstract that claims a human effect carries no numbers, no reference and no study we could find [3]. This guide is shorter than usual because the human record is.

What it is

Cortagen is a tetrapeptide: alanine, glutamic acid, aspartic acid and proline (AEDP). Researchers linked to Vladimir Khavinson’s Institute of Bioregulation and Gerontology in St Petersburg designed it from the amino-acid make-up of Cortexin, a polypeptide extract of animal brain cortex used in clinics [3,5]. It belongs to the same family of “peptide bioregulators” as epitalon (AEDG), which differs from it by a single amino acid. The theory behind the family is that very short peptides can enter cells and adjust gene activity in the tissue they came from — a mechanism theory held by one research school, not a measured effect in people.

Don’t confuse cortagen with Cortexin itself. Cortexin is a mixture with its own, separate literature; cortagen is a single synthetic molecule. Some online sources cite Cortexin studies as if they were cortagen evidence.

The human evidence

There is no clinical trial of cortagen in any indexed journal, and none registered. The human record is that thin.

The English abstract of one paper states that, in humans, cortagen showed “a pronounced therapeutic effect” on recovery of injured peripheral nerves [3]. The abstract gives no reference, no numbers and no study details, and we could not locate the study it describes. It is the only claim in this literature that points at people, and it rests on that one sentence.

The only work involving human material we found is a lab study: white blood cells taken from people aged 75 to 88 were exposed to several short peptides, including cortagen, and all of them loosened tightly packed chromatin, the way DNA is stored in the nucleus [6]. That is a test-tube finding about gene packaging, and it stops at the dish.

What the animal work shows

Nerve regeneration in rats

The clearest numbers come from the earliest study. Rats had their sciatic nerve cut and stitched, then received 10 micrograms per kg of cortagen by injection daily for 10 days [1]. Compared with controls, regenerating nerve fibres grew 27% faster and conducted signals 40% faster [1]. A follow-up from the same group reported that the benefit to nerve function persisted after dosing stopped, though its English abstract gives no figures [2]. That is the clearest quantified result in a literature that mostly reports without numbers, and it is the one worth following closely.

Brain and behaviour

• Chronic brain ischaemia in rats. Cortexin and cortagen both sped up recovery of disturbed behaviour and limited oxidative damage in brain tissue [4]. The paper is in Russian, and the English abstract has no numbers.
• Behaviour in mice. The closest thing to outside work is a 2009 study led from Italy’s national health institute, with one co-author from Geropharm, a St Petersburg pharmaceutical company [5]. In mice, one cortagen dose (0.03 mg/kg) increased movement both after one dose and after five days. After five days of dosing, the other two doses, and the Cortexin reference dose, produced anxiety-like behaviour in the maze test [5]. That is a mixed result, and it is sometimes summarised online as cortagen being free of anxiety effects.
• Gene activity in mouse hearts. Five days of cortagen injections in mice changed the activity of 234 gene clones, matching 110 known genes, out of more than 15,000 measured [3]. The peptide reaches tissue and alters gene activity there — in the heart, not the brain.

Reading the claims you’ll see

Product pages for cortagen tend to list memory, focus, nerve repair and brain protection. Put each claim next to the studies above and it maps to a single rodent study, usually from one group, usually reported in a short abstract without numbers. The nerve-repair claim traces back to rats with a cut sciatic nerve [1]. The brain-protection claim traces to rats with reduced blood flow to the brain [4]. Memory and focus are the claims with the least behind them: no study in any species tested cortagen on its own for either.

Safety and side effects reported

Human tolerability has never been measured, because no human study has been run. The animal papers don’t report toxicity, but they weren’t designed as safety studies and most report no figures on adverse effects. The mouse behaviour study’s finding of anxiety-like behaviour after repeated dosing at some doses is the only signal of an unwanted effect we found [5], and it is why the “calm, side-effect-free” summaries you see do not match the paper.

Legal and regulatory status

Cortagen is not approved as a medicine in the UK, the US or the EU. It is sold online as a research chemical, so the only thing standing between you and the molecule is the supplier’s paperwork. Treat sourcing as the one variable you can actually control, and check four things rather than one: purity (an HPLC figure, not a claim), sterility, endotoxin and heavy metals. A certificate of analysis reporting purity alone has answered one question out of four; see how to read a certificate of analysis. It isn’t named on the WADA Prohibited List, but as a substance with no approval for human use it would fall under WADA’s S0 category for athletes.

What is still open

• Whether cortagen does anything measurable in people, at any dose.
• Whether the rat nerve results would repeat outside the group that designed the molecule.
• Where it goes in the body: absorption, half-life and tissue levels in humans are unpublished.
• How the mouse anxiety signal after repeated dosing translates to people, if at all.
• What people buying “cortagen” are actually getting.

What this means

Our position is that cortagen should be judged as what it is: a preclinical molecule with one real, quantified finding and an empty human record. The finding is worth naming. In rats, after a nerve was cut and re-stitched, cortagen produced faster fibre regrowth and faster conduction signals than controls [1], and the effect outlasted dosing [2]. That is more than a hypothesis, and it is why we cover the compound at all rather than ignore it.

The missing trial is not a mystery. A randomised, placebo-controlled study large enough to settle whether cortagen helps an injured human nerve costs millions. That money comes from a company, and a company pays for it to own the result: a patent, an exclusivity period, a price it can set. Cortagen is not an approved medicine anywhere, is not owned in a way that would repay that cost, and is sold only as a research chemical. So no institution has a financial reason to run the trial. That is not a molecule that failed. It is a preclinical molecule nobody has been paid to finish.

What the evidence does not support is the pitch. Cortagen is sold as a brain peptide for memory and focus, and no study in any species tested it for either on its own. The animal results are about nerve repair after injury and gene activity in heart tissue [1,3,4], and the one human-facing claim in the literature is a single sentence with no study behind it [3]. A reader buying cortagen for focus is not buying the compound the rats got.

So our read is narrow, and we will defend it. The rat nerve work is a real lead that deserves a small, registered first-in-human safety and dose study, and we would like to see one funded. Until it exists, we would not use cortagen and would not recommend it. Not because it has been shown to fail, but because there is no human result to act on, and the mouse anxiety signal at repeated doses is the only safety data of any kind [5]. If you weigh it anyway, treat the vial rather than the peptide as the risk you can control: a lot-level certificate of analysis naming the peptide, an HPLC purity figure, and testing for sterility, endotoxin and heavy metals.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.